Pentoxifylline for Bipolar Depression: A Proof-of-Concept Feasibility Study

ClinicalTrials.gov · COMPLETED, 2021

6 participants

Abstract

Growing theoretical and clinical evidence has suggested that pentoxifylline may have an effect in improving depressive symptoms. Herein, we aim to evaluate the effect of pentoxifylline in patients with bipolar depression over an 8-week trial.

Conditions: Bipolar Depression.

Primary outcome: The recruitment rate; The retention rate.

Enrollment: 6 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 6 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• Diarylethenes for Memories and Switches Chemical Reviews, 2000
• Long-Term Potentiation and Memory Physiological Reviews, 2004
• Social Memory Studies: From “Collective Memory” to the Historical Sociology of Mnemonic Practices Annual Review of Sociology, 1998
• The Cognitive Neuroscience of Working Memory Annual Review of Psychology, 2014
• Memory aging and brain maintenance Trends in Cognitive Sciences, 2012
• Effector and Memory CTL Differentiation Annual Review of Immunology, 2006

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free